Markets

Insider Trading

Hedge Funds

Retirement

Opinion

12 Best Medical Devices Stocks to Invest In According to Hedge Funds

Page 1 of 12

It is challenging to identify segments within the markets that appear to be defensive plays, yet offer innovation potential. The medical devices industry is one such space that attracts investors due to the amalgamation of many such factors. On one hand, it appears defensive in nature due to strong entry barriers, underlying regulatory scrutiny, and consistent demand patterns. On the other hand, it offers immense growth potential due to rapid innovations that keep on reshaping the segment from time to time. The medical devices industry has strong interlinkages with medical technology evolution, which forms the basis for engineering and functionality of equipment used in the broader healthcare sector. Many businesses are integrating inorganically to make themselves more efficient and profitable, with the ultimate aim of enhancing patient experience.

On December 16, PwC shared its 2026 deals outlook for the U.S. Medical Technology landscape, following a surge in deal value to above $97 billion in 2025. The firm identified digital transformation trends such as AI-driven analytics, robotics, and connected-care ecosystems to be at the heart of capital deployment towards inorganic growth. Companies will aim to divest many of their subscale segments in pursuit of more scalable operations. The firm also underlined a growing role of private equity firms in Medtech deals, not just as capital providers but also as operational stakeholders. This provides a new way of accelerating innovation within this segment.

With that background, let’s explore our 12 best Medical Devices stocks to invest in according to Hedge Funds.

Copyright: nimon / 123RF Stock Photo

Our Methodology

To identify relevant stocks for this article, we conducted a screening of U.S.-listed medical device companies having market capitalizations above $2 billion. We then added a filter to include companies with share prices above $5 to ensure we do not include penny stocks in our list. Also, we shortlisted only stocks with at least 10% upside potential according to TipRanks consensus, as of the January 28 close.

In the last part of the screening, we identified the number of hedge funds that held positions in these stocks by the end of the third quarter of 2025. Finally, we selected 12 stocks with the highest number of hedge funds holding stakes and ranked them in ascending order.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

12. Haemonetics Corporation (NYSE:HAE)

Number of Hedge Fund Holders: 36

Haemonetics Corporation (NYSE:HAE) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds.

On January 12, Michael Petusky from Barrington maintained his Outperform rating on Haemonetics Corporation (NYSE:HAE). He also revised his estimated price target upward from $90 to $93, implying an upside of almost 41%.

Petusky’s rating and target price adjustment came at the back of the company’s recent acquisition of Vivasure Medical, an Ireland-based advanced polymer implants and delivery systems manufacturer. The analyst sees this deal in a favorable light, which makes him optimistic about the stock performance.

Earlier, on December 17, Mizuho Securities analyst Anthony Petrone had also reaffirmed his Outperform rating on Haemonetics Corporation (NYSE:HAE), while increasing the price target from $75 to $90. His revisions now lead to an upside potential of over 36% from the current level.

Petrone’s revisions were part of Mizuho Securities’ adjustments across the medical devices and diagnostics space, in line with its 2026 outlook. The analyst noted that there is still room for valuations to expand further despite a rally witnessed post-Q3 announcements. He anticipates this “under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector.”

Haemonetics Corporation (NYSE:HAE) offers hospital technology solutions and specializes in plasma and blood management. Some of the offerings include plasma collection systems, donor management services, and supporting software that cut down healthcare costs for patients, improve patient outcomes, and enhance blood product quality.

Page 1 of 12

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!